



## Javelin Pharmaceuticals to Host Second Quarter 2009 Conference Call

CAMBRIDGE, Mass., Aug 04, 2009 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV) announced today that Martin J. Driscoll, Chief Executive Officer, Dr. Daniel B. Carr, Chief Medical Officer and President and Stephen J. Tulipano, CPA, Chief Financial Officer, will host a conference call to discuss the Company's quarterly financial condition, results of operations and key Company activities for the period ending June 30, 2009. The call will be held Tuesday, August 11<sup>th</sup> at 8:30am EDT.

The Company invites all interested parties to participate. The call will be simulcast live over the internet through the following URL: <http://ir.javelinpharmaceuticals.com/events.cfm> and will be archived on the Company's website at [www.javelinpharmaceuticals.com](http://www.javelinpharmaceuticals.com).

### CONFERENCE CALL ALERT

What: Javelin Pharmaceuticals, Inc. 2009 Second Quarter Earnings Call

When: August 11, 2009 at 8:30am EDT

How: Those interested in participating in the call should dial toll free (888)364-3107 within the United States and Canada and + (719)325-2235 internationally

### About Javelin Pharmaceuticals, Inc.

With corporate headquarters in Cambridge, MA, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the acute pain management market. The Company has one marketed drug in the UK and three drug candidates in US Phase 3 clinical development. For additional information about Javelin, please visit the Company's website at <http://www.javelinpharmaceuticals.com>.

### Forward Looking Statement

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.

JAV-E

SOURCE: Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc.  
Stephen J. Tulipano, CPA, 617-349-4500  
Chief Financial Officer  
[stulipano@javelinpharma.com](mailto:stulipano@javelinpharma.com)

or

Investor Relations & Media  
Rick Pierce, 617-349-4500  
Vice President, Investor Relations  
[rpierce@javelinpharma.com](mailto:rpierce@javelinpharma.com)

Copyright Business Wire 2009